

# Lixia Diao

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/954842/publications.pdf>

Version: 2024-02-01

104  
papers

12,709  
citations

44069

48  
h-index

31849

101  
g-index

109  
all docs

109  
docs citations

109  
times ranked

20736  
citing authors

#	ARTICLE	IF	CITATIONS
1	An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance. <i>Clinical Cancer Research</i> , 2013, 19, 279-290.	7.0	848
2	Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. <i>Nature Communications</i> , 2014, 5, 5241.	12.8	780
3	Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities. <i>Cancer Discovery</i> , 2015, 5, 860-877.	9.4	696
4	Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2019, 9, 646-661.	9.4	555
5	TANRIC: An Interactive Open Platform to Explore the Function of lncRNAs in Cancer. <i>Cancer Research</i> , 2015, 75, 3728-3737.	0.9	518
6	A pan-cancer proteomic perspective on The Cancer Genome Atlas. <i>Nature Communications</i> , 2014, 5, 3887.	12.8	456
7	STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. <i>Cancer Research</i> , 2016, 76, 999-1008.	0.9	451
8	Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1. <i>Cancer Discovery</i> , 2012, 2, 798-811.	9.4	432
9	The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers. <i>Cancer Cell</i> , 2015, 28, 515-528.	16.8	426
10	Integrative Molecular Characterization of Malignant Pleural Mesothelioma. <i>Cancer Discovery</i> , 2018, 8, 1548-1565.	9.4	422
11	Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. <i>Cancer Cell</i> , 2021, 39, 346-360.e7.	16.8	422
12	A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition. <i>Clinical Cancer Research</i> , 2016, 22, 609-620.	7.0	388
13	Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 3630-3642.	7.0	353
14	CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade. <i>Cancer Discovery</i> , 2018, 8, 1156-1175.	9.4	323
15	Assessing the clinical utility of cancer genomic and proteomic data across tumor types. <i>Nature Biotechnology</i> , 2014, 32, 644-652.	17.5	257
16	Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. <i>Cell Reports</i> , 2018, 23, 194-212.e6.	6.4	245
17	Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion. <i>Nature Communications</i> , 2020, 11, 4520.	12.8	218
18	PancanQTL: systematic identification of cis-eQTLs and trans-eQTLs in 33 cancer types. <i>Nucleic Acids Research</i> , 2018, 46, D971-D976.	14.5	191

#	ARTICLE	IF	CITATIONS
19	A Pan-cancer Analysis of the Expression and Clinical Relevance of Small Nucleolar RNAs in Human Cancer. <i>Cell Reports</i> , 2017, 21, 1968-1981.	6.4	186
20	Structure-based classification predicts drug response in EGFR-mutant NSCLC. <i>Nature</i> , 2021, 597, 732-737.	27.8	185
21	The Genomic Landscape and Pharmacogenomic Interactions of Clock Genes in Cancer Chronotherapy. <i>Cell Systems</i> , 2018, 6, 314-328.e2.	6.2	183
22	Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 6322-6328.	7.0	171
23	Transcriptional landscape and clinical utility of enhancer RNAs for eRNA-targeted therapy in cancer. <i>Nature Communications</i> , 2019, 10, 4562.	12.8	165
24	Characterization of hypoxia-associated molecular features to aid hypoxia-targeted therapy. <i>Nature Metabolism</i> , 2019, 1, 431-444.	11.9	158
25	Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. <i>Cancer Cell</i> , 2019, 36, 444-457.e7.	16.8	145
26	Sex-associated molecular differences for cancer immunotherapy. <i>Nature Communications</i> , 2020, 11, 1779.	12.8	144
27	The Pan-Cancer analysis of pseudogene expression reveals biologically and clinically relevant tumour subtypes. <i>Nature Communications</i> , 2014, 5, 3963.	12.8	143
28	Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy. <i>Nature Communications</i> , 2020, 11, 4946.	12.8	120
29	Comprehensive characterization of circular RNAs in ~1000 human cancer cell lines. <i>Genome Medicine</i> , 2019, 11, 55.	8.2	116
30	LNCEditing: a database for functional effects of RNA editing in lncRNAs. <i>Nucleic Acids Research</i> , 2017, 45, D79-D84.	14.5	111
31	Comprehensive Characterization of Alternative Polyadenylation in Human Cancer. <i>Journal of the National Cancer Institute</i> , 2018, 110, 379-389.	6.3	111
32	Reciprocal Regulation of c-Src and STAT3 in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 6852-6861.	7.0	105
33	Circulating microRNAs in Pancreatic Juice as Candidate Biomarkers of Pancreatic Cancer. <i>Journal of Cancer</i> , 2014, 5, 696-705.	2.5	103
34	A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	101
35	Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with $\beta$ -blockers. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	96
36	STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype. <i>Journal of Thoracic Oncology</i> , 2020, 15, 777-791.	1.1	94

#	ARTICLE	IF	CITATIONS
37	Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6239-6253.	7.0	93
38	Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 2152-2163.	1.1	80
39	AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers. <i>Molecular Cancer Research</i> , 2017, 15, 45-58.	3.4	73
40	A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2738-2750.	4.1	72
41	INO80 governs superenhancer-mediated oncogenic transcription and tumor growth in melanoma. <i>Genes and Development</i> , 2016, 30, 1440-1453.	5.9	65
42	Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer. <i>PLoS ONE</i> , 2016, 11, e0152584.	2.5	65
43	In Vivo Delivery of miR-34a Sensitizes Lung Tumors to Radiation Through RAD51 Regulation. <i>Molecular Therapy - Nucleic Acids</i> , 2015, 4, e270.	5.1	63
44	Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target. <i>Journal of Thoracic Oncology</i> , 2021, 16, 583-600.	1.1	62
45	Global analysis of tRNA and translation factor expression reveals a dynamic landscape of translational regulation in human cancers. <i>Communications Biology</i> , 2018, 1, 234.	4.4	58
46	Proteomic Profiling Identifies Pathways Dysregulated in Non-small Cell Lung Cancer and an Inverse Association of AMPK and Adhesion Pathways with Recurrence. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1894-1904.	1.1	57
47	Sex specific function of epithelial STAT3 signaling in pathogenesis of K-ras mutant lung cancer. <i>Nature Communications</i> , 2018, 9, 4589.	12.8	57
48	Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer. <i>Modern Pathology</i> , 2018, 31, 947-955.	5.5	56
49	Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1396-1404.	6.3	56
50	An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2. <i>Clinical Cancer Research</i> , 2015, 21, 3480-3491.	7.0	48
51	Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 127-139.	1.1	48
52	The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network. <i>Journal of Clinical Investigation</i> , 2018, 128, 1267-1282.	8.2	48
53	Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-to-mesenchymal transition. <i>BMC Genomics</i> , 2014, 15, 1079.	2.8	45
54	Pancan-meQTL: a database to systematically evaluate the effects of genetic variants on methylation in human cancer. <i>Nucleic Acids Research</i> , 2019, 47, D1066-D1072.	14.5	45

#	ARTICLE	IF	CITATIONS
55	Focal adhesion kinase. <i>Cancer Biology and Therapy</i> , 2014, 15, 919-929.	3.4	42
56	ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	42
57	CircView: a visualization and exploration tool for circular RNAs. <i>Briefings in Bioinformatics</i> , 2019, 20, 745-751.	6.5	42
58	Epithelialâ€“Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitorâ€“Mediated Apoptosis in Nonâ€“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 1674-1686.	7.0	41
59	APAAtlas: decoding alternative polyadenylation across human tissues. <i>Nucleic Acids Research</i> , 2020, 48, D34-D39.	14.5	41
60	A Multi-Omics Perspective of Quantitative Trait Loci in Precision Medicine. <i>Trends in Genetics</i> , 2020, 36, 318-336.	6.7	41
61	Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers. <i>Nature Communications</i> , 2021, 12, 2606.	12.8	41
62	High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer. , 2019, 7, 351.		39
63	Multimiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity. <i>Genome Biology</i> , 2020, 21, 271.	8.8	36
64	Altered Regulation of HIF-1Î± in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype. <i>Journal of Thoracic Oncology</i> , 2021, 16, 439-451.	1.1	34
65	Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2â€“Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1821-1839.	1.1	34
66	Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy. , 2022, 10, e003779.		34
67	MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer. <i>Modern Pathology</i> , 2016, 29, 330-346.	5.5	33
68	Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively immunoprofiled cohort. , 2020, 8, e000405.		33
69	Small non-coding RNAs in human cancer: function, clinical utility, and characterization. <i>Oncogene</i> , 2021, 40, 1570-1577.	5.9	33
70	AXL Inhibition Induces DNA Damage and Replication Stress in Nonâ€“Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors. <i>Molecular Cancer Research</i> , 2021, 19, 485-497.	3.4	32
71	Single-cell reconstruction of differentiation trajectory reveals a critical role of ETS1 in human cardiac lineage commitment. <i>BMC Biology</i> , 2019, 17, 89.	3.8	31
72	Characterization of the dual functional effects of heat shock proteins (HSPs) in cancer hallmarks to aid development of HSP inhibitors. <i>Genome Medicine</i> , 2020, 12, 101.	8.2	31

#	ARTICLE	IF	CITATIONS
73	Dasatinib induces DNA damage and activates DNA repair pathways leading to senescence in non-small cell lung cancer cell lines with kinase-inactivating <i>BRAF</i> mutations. <i>Oncotarget</i> , 2016, 7, 565-579.	1.8	31
74	HeRA: an atlas of enhancer RNAs across human tissues. <i>Nucleic Acids Research</i> , 2021, 49, D932-D938.	14.5	27
75	Hsp90 Inhibitor Ganetespib Sensitizes Non-Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation. <i>Clinical Cancer Research</i> , 2016, 22, 5876-5886.	7.0	25
76	THO Complex-Dependent Posttranscriptional Control Contributes to Vascular Smooth Muscle Cell Fate Decision. <i>Circulation Research</i> , 2018, 123, 538-549.	4.5	25
77	Myeloid loss of Beclin 1 promotes PD-L1hi precursor B cell lymphoma development. <i>Journal of Clinical Investigation</i> , 2019, 129, 5261-5277.	8.2	25
78	Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer. <i>Nature Communications</i> , 2021, 12, 6655.	12.8	24
79	Growth and metastasis of lung adenocarcinoma is potentiated by BMP4-mediated immunosuppression. <i>Oncolmmunology</i> , 2016, 5, e1234570.	4.6	23
80	drexplore: A tool to explore dose-response relationships and drug-drug interactions. <i>Bioinformatics</i> , 2015, 31, 1692-1694.	4.1	22
81	Expression of chimeric antigen receptor therapy targets detected by single-cell sequencing of normal cells may contribute to off-tumor toxicity. <i>Cancer Cell</i> , 2021, 39, 1558-1559.	16.8	22
82	Decreased expression of microRNA-26b in locally advanced and inflammatory breast cancer. <i>Human Pathology</i> , 2018, 77, 121-129.	2.0	20
83	Targeting MYC-enhanced glycolysis for the treatment of small cell lung cancer. <i>Cancer &amp; Metabolism</i> , 2021, 9, 33.	5.0	20
84	The EMT activator ZEB1 accelerates endosomal trafficking to establish a polarity axis in lung adenocarcinoma cells. <i>Nature Communications</i> , 2021, 12, 6354.	12.8	20
85	Integrated MicroRNA-mRNA Profiling Identifies Oncostatin M as a Marker of Mesenchymal-Like ER-Negative/HER2-Negative Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2017, 18, 194.	4.1	18
86	tRiC: a user-friendly data portal to explore the expression landscape of tRNAs in human cancers. <i>RNA Biology</i> , 2020, 17, 1674-1679.	3.1	18
87	The genetic and pharmacogenomic landscape of snoRNAs in human cancer. <i>Molecular Cancer</i> , 2020, 19, 108.	19.2	17
88	Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-Mesenchymal Transition in NSCLC. <i>Cancer Research</i> , 2021, 81, 1398-1412.	0.9	16
89	GPEdit: the genetic and pharmacogenomic landscape of A-to-I RNA editing in cancers. <i>Nucleic Acids Research</i> , 2022, 50, D1231-D1237.	14.5	16
90	KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib. <i>Clinical Cancer Research</i> , 2016, 22, 1940-1950.	7.0	15

#	ARTICLE	IF	CITATIONS
91	Biomarker-Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2018, 13, 246-257.	1.1	14
92	CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1965-1976.	4.2	14
93	Profiling of immune features to predict immunotherapy efficacy. <i>Innovation(China)</i> , 2021, 3, 100194.	9.1	13
94	Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and therapeutic resistance in KRAS-mutant lung cancer. <i>JCI Insight</i> , 2021, 6, .	5.0	12
95	Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 14268-14284.	1.8	12
96	A murine preclinical syngeneic transplantation model for breast cancer precision medicine. <i>Science Advances</i> , 2017, 3, e1600957.	10.3	10
97	Adverse events associated with potential drugs for COVID-19: a case study from real-world data. <i>Briefings in Bioinformatics</i> , 2021, 22, 1232-1238.	6.5	10
98	Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of <i>RICTOR/KRAS</i> -altered non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 33995-34008.	1.8	9
99	The microRNA-183/96/182 cluster inhibits lung cancer progression and metastasis by inducing an interleukin-2-mediated antitumor CD8 <sup>+</sup> cytotoxic T-cell response. <i>Genes and Development</i> , 2022, 36, 582-600.	5.9	9
100	Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 109.	8.6	7
101	Estrogen Promotes Resistance to Bevacizumab in Murine Models of NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 2051-2064.	1.1	6
102	Valproic acid combined with cisplatin-based chemoradiation in locally advanced head and neck squamous cell carcinoma patients and associated biomarkers. <i>Ecancermedalscience</i> , 2020, 14, 1155.	1.1	6
103	Enhanced Vulnerability of LKB1-Deficient NSCLC to Disruption of ATP Pools and Redox Homeostasis by 8-Cl-Ado. <i>Molecular Cancer Research</i> , 2022, 20, 280-292.	3.4	4
104	Selecting Reliable mRNA Expression Measurements across Platforms Improves Downstream Analysis. <i>Cancer Informatics</i> , 2016, 15, CIN.S38590.	1.9	2